Tagged with

Dream CIS South Korea has a much shorter history of clinical trials than many other advanced economies. In your view, what is the potential for South Korea’s clinical trial industry today? The quality of Korean medical service is already top notch; it is truly world class. However, the environment here has been…

Teva Czech Republic Mr. Zahradnik, you have long been an active member of the Czech generic drug makers’ association CAFF (Czech Association of Pharmaceutical Firms), chairing the organization. Dr. Zörner, executive director of the CAFF, has remarked that the Czech Republic is a challenging market, but also one in which the authorities have…

Bayer Healthcare South Africa Since we interviewed you in 2005, there have been many changes in the market, from consolidation, an increasing generic penetration, to new healthcare reforms… How have you integrated these changes in the company’s development, and to what extent does Bayer’s recent development reflect the market changes? The first change has…

Histostem After spending a large part of your career as a university professor, what drove you to create your own company, Histostem, in 2000? In 1993, I actually established a bone marrow bank for the first time in Korea when I was a professor of the Catholic University in Seoul, Korea.…

Mr. Polach, can you please begin with an introduction to CzechBio and explicate the association’s mission on this market? CzechBio is an association of Czech biotech companies that started its operations in December 2008. CzechBio’s ambition is to create a national platform for the biotech sector in the Czech Republic…

Aspen The Aspen Group identified Latin America as a “large developing market where it can leverage its substantial intellectual property portfolio and manufacturing infrastructure”. What was the original strategy behind getting the best from the Mexican market – specifically with the acquisition of the Latin America business from India-based Strides Arcolab…

Infinite Clinical Research We understand that Mexico has a lot of advantages for holding clinical trials, including the large population, access to specialized patient populations, higher patient retention rates and cheaper costs by up to 30% when compared to the United States and Europe. In your opinion, what is the most common reason…

Astellas Czech Republic Mr. Chadim, after Astellas was formed from the merger between Yamanouchi and Fujisawa, it became your job to lead its Czech subsidiary. Tapani Sura, your colleague at Astellas Poland, has told Focus Reports that in Poland, Astellas’ first year was a nightmare. “It is safe to say,” he remarked, that…

Bomi de Mexico You took over BOMI as President and CEO only last year. Could you give us a brief background on BOMI Mexico and yourself? BOMI Mexico was founded in 1995. The mother company is Italian – and the Italian founder saw the potential in Latin America before most other pharmaceutical logistics…

Let us begin by introducing BACHI, its area of focus and scope of activities? BACHI is a fairly young independent association of the consumer healthcare industry, counting 28 of the sectors’ most important players. Currently we are in our fourth operational year, and the association is still growing with new…

Stallergenes Czech Republic Mr. Tor, prior to joining Stallergenes in 2010, you had been with MSD for nearly two decades. After such a prolonged experience at a major global pharma player, why did you decide to move down the value chain to a smaller, considerably more specialized biopharmaceutical company like Stallergenes, and what…

Mr. Pfannenschmidt, you have been working for Boehringer Ingelheim for three decades, outlasting several company chairman and witnessing the birth and evolution of the corporate vision “Value through Innovation”. Before we delve specifically into the Czech market, can you tell our readers how this company has evolved through all these…